Add-on therapy in metformin-treated patients with type 2 diabetes at moderate cardiovascular risk: a nationwide study.
David TheinMia Nielsen ChristiansenUlrik Madvig MogensenJohan Skov BundgaardRasmus RørthChristian MadelaireEmil Loldrup FosbølMorten SchouChristian Torp-PedersenGunnar GislasonLars KøberSøren Lund KristensenPublished in: Cardiovascular diabetology (2020)
In a nationwide cohort of metformin-treated T2D patients and no history of cardiovascular events, the addition of either GLP-1 RA or SGLT-2 inhibitor to metformin treatment was associated with a similar risk of hospitalisation for HF and death, and a lower risk of MACE for GLP-1 RA when compared with add-on DPP-4 inhibitors. By contrast, initiation of treatment with SU and insulin were associated with a higher risk of MACE. Additionally, insulin was associated with an increased risk of all-cause mortality and hospitalisation for HF.
Keyphrases
- cardiovascular events
- type diabetes
- end stage renal disease
- newly diagnosed
- rheumatoid arthritis
- coronary artery disease
- cardiovascular disease
- chronic kidney disease
- ejection fraction
- peritoneal dialysis
- magnetic resonance
- computed tomography
- metabolic syndrome
- glycemic control
- high intensity
- cross sectional
- replacement therapy
- atrial fibrillation
- weight loss